Analysis updated Jul 30, 2026 — scores and signals refreshed daily.
Prime Medicine Inc. Common Stock (PRME) stock research. Updated Jul 30, 2026. Q-Score 50/100 — Hold. Fair value, forecast, technicals, and insider activity.
Current Q-Score verdict: Hold (50.0) (grade C). 24 signals analyzed (21 differentiated alt-data).
StoQuant's analysis of Prime Medicine Inc. Common Stock (PRME) is refreshed every trading day. The Q-Score combines discounted cash flow valuation, earnings quality, competitive moat, analyst consensus, ML return forecasts, technical momentum and market sentiment into a single 0–100 composite. Insider transactions from SEC Form 4 filings, the Graham intrinsic value estimate and signal coverage are recomputed as new data arrives, so this page always reflects the latest available information.
PRME stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-07-10 | $4.26 | $3.62 | $3.78 |
| 2026-07-20 | $3.22 | $3.03 | $3.05 |
| 2026-07-28 | $3.10 | $2.87 | $3.09 |
| 2026-08-05 | $3.12 | $2.89 | $3.08 |
| 2026-08-13 | $3.29 | $3.13 | $3.17 |
| 2026-08-21 | $3.48 | $3.24 | $3.39 |
| 2026-08-31 | $3.63 | $3.46 | $3.59 |
| 2026-09-09 | $3.54 | $3.29 | $3.47 |
| 2026-09-17 | $3.39 | $3.10 | $3.14 |
| 2026-09-25 | $3.44 | $2.88 | $2.90 |
| 2026-10-05 | $3.26 | $2.88 | $3.21 |
How Prime Medicine Inc. Common Stock stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| AZN | AstraZeneca PLC | $290.7B | — |
| NVS | Novartis AG | $287.1B | — |
| NVO | Novo Nordisk A/S | $200.3B | — |
| SNY | Sanofi | $107.6B | — |
| GSK | GSK plc | $102.1B | — |
View all Health Care stocks by valuation and signals →
Prime Medicine Inc. Common Stock (PRME) scores Hold (50.0), and the composite conceals a 82-point disagreement between its dimensions. It is strongest on competitive moat at 94 and analyst consensus at 76, and weakest on technicals at 12. A stock can carry competitive moat that high while technicals sits at 12; the composite averages that tension away, which is why the breakdown is worth reading before the headline number. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| competitive moat | 94 |
| analyst consensus | 76 |
| technicals | 12 |
StoQuant analyzes 24 signals (21 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on Prime Medicine Inc. Common Stock (PRME): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
Browse daily research picks • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and IC-weighted signals (live edge on /proof). We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/PRME"><img src="https://stoquant.com/badge/PRME.svg" alt="Prime Medicine Inc. Common Stock (PRME) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Free StoQuant digest by email. No account needed. See today's research picks.